Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on MetaVia (MTVA – Research Report) and keeping the price target at $12.00.
Ed Arce has given his Buy rating due to a combination of factors surrounding MetaVia’s promising developments in their clinical trials. The anticipated release of top-line data from Part 2 of the Phase 1 study for DA-1726, an oxyntomodulin analogue targeting GLP-1 and GCG receptors for weight loss, is expected to provide crucial efficacy confirmation. The drug has already demonstrated favorable safety and tolerability in earlier trials, and the upcoming data could support its progression into further study phases.
Moreover, the planned randomized, double-blind, placebo-controlled Part 3 of the study aims to provide comprehensive insights into weight loss outcomes, including the composition of weight loss and sustainability post-treatment. This phase is expected to enroll around 80 participants and will offer a direct comparison against existing obesity therapies. Additionally, MetaVia’s plans for an end-of-Phase 2 meeting with the FDA regarding DA-1241 for MASH, coupled with promising early data, further bolster the positive outlook. These strategic advancements in MetaVia’s pipeline underpin Ed Arce’s Buy recommendation.